---
title: Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health
nct_id: NCT07376681
overall_status: ENROLLING_BY_INVITATION
sponsor: Taizhou Hospital
study_type: OBSERVATIONAL
primary_condition: Prognosis
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07376681.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07376681"
ct_last_update_post_date: 2026-01-29
last_seen_at: "2026-05-12T06:29:55.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health

**NCT ID:** [NCT07376681](https://clinicaltrials.gov/study/NCT07376681)

## Key Facts

- **Status:** ENROLLING_BY_INVITATION
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2000
- **Lead Sponsor:** Taizhou Hospital
- **Collaborators:** Second Affiliated Hospital, Sun Yat-Sen University, Ruijin Hospital
- **Conditions:** Prognosis, Fertility, Breast Cancer, Young People
- **Start Date:** 2026-01
- **Completion Date:** 2026-10
- **CT.gov Last Update:** 2026-01-29

## Brief Summary

The goal of this observational study is to clarify the fertility status of young breast cancer patients, verify the independent impact of fertility behavior on the prognosis of patients with different molecular types, and evaluate the association between treatment regimens and offspring health.

## Detailed Description

This was a multicenter retrospective study on fertility outcomes and their prognosis and offspring health in young breast cancer patients. Based on the breast cancer database, the investigators registered the baseline data of young breast cancer patients (≤40 years old), including age at initial diagnosis, molecular typing, tumor stage, treatment plan, fertility protection measures, etc., and followed up by telephone/email and other means to collect their fertility status, recurrence and offspring growth and development data. The primary endpoints were the disease-free survival (DFS), overall survival (OS) after childbirth and childrens' growth and development. The secondary endpoints were the patient's fertility live birth rate, pregnancy outcomes and complications, use of fertility preservation techniques, breastfeeding status, etc. The investigators used the Kaplan-Meier method to draw the survival curve of the patients after childbirth, and analyzed the growth trajectory of the offspring born after diagnosis by the Lambda-Mu-Sigma method, and plotted the growth and development curve.The investigators used Log-rank to test the significance of differences in pregnancy rates between variables. The investigators used Univariate Cox regression analysis to screen factors related to prognosis, and then used multivariate Cox regression analysis to adjust for potential confounding factors to clarify independent prognostic indicators of disease. Finally, descriptive analyses were performed for other secondary outcomes.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Only subjects who meet all of the following inclusion criteria can be enrolled in this trial:

1. Female patients diagnosed with breast cancer aged ≤ 40 years;
2. Patients with pathologically confirmed breast cancer, and TNM stage 0-III, the disease is in a stable or progressive state;
3. Complete medical records and clinical follow-up data were available. Informed consent.

Exclusion Criteria:

Anyone who has one of the following conditions cannot be included in this trial:

1. Female patients with a diagnosis age\>40 years;
2. Stage IV breast cancer at first diagnosis;
3. The presence of other reproductive system diseases caused by oligomenorrhea or amenorrhea and infertility; Loss of clinical data or loss to follow-up.
```

## Primary Outcomes

- **The overall-surviva(OS) period of childbirth after diagnosis** _(time frame: About 2 years after the start of the research.)_ — The starting time of OS regarded as after completing the childbearing behavior.Death is regarded as the end time of OS.
- **The disease-free survival(DFS) period of childbirth after diagnosis** _(time frame: About 2 years after the start of the research)_ — The starting time of DFS is regarded as after completing the childbearing behavior.Repase or distant metastasis is regarded as the end time of DFS.
- **The growth and development of offspring** _(time frame: About 2 years after the start of the research)_ — The growth and development of young breast cancer patients after diagnosis. By collecting their height, weight and other data, using the Lambda-Mu-Sigma method recommended by WHO, the obtained data is fitted to the offspring growth curve of young breast cancer patients and compared with the standard curve, in order to evaluate whether the patients' offspring grows abnormally.
- **The occurrence of diseases in the descendants of young breast cancer patients.** _(time frame: About 2 years after the start of the research)_ — Descriptive research. Describe the number of serious disease events in the offspring of young breast cancer patients after diagnosis, such as the number of secondary tumors in childhood

## Secondary Outcomes

- **Fertility rate of young breast cancer patients.** _(time frame: About 2 years after the start of the research.)_
- **Complications during pregnancy after diagnosis of young breast cancer patients.** _(time frame: About 2 years after the start of the research)_
- **The use of fertility preservation in the reproductive process of young breast cancer patients.** _(time frame: About 2 years after the start of the research)_
- **Breastfeeding.** _(time frame: About 2 years after the start of the research.)_

## Locations (1)

- Taizhou Central Hosipital, Taizhou, Zhejiang, China

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.taizhou central hosipital|taizhou|zhejiang|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07376681.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07376681*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*